CAP-IT Center for LNP RNA Immunoprevention

CAP-IT LNP RNA 免疫预防中心

基本信息

批准号：
10505675
负责人：
NASSER Khaled ALTORKI
金额：
$ 118.06万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10505675
关键词：
Antigens Architecture Autologous Award Biotechnology COVID-19 COVID-19 vaccine Cancer Burden Cessation of life Clinic Clinical Clinical Trials Clonal Evolution Communicable Diseases Computer Analysis Data Databases Division of Cancer Prevention Ensure Genomics Goals Health Insurance Portability and Accountability Act Hereditary Nonpolyposis Colorectal Neoplasms Immune Immunologic Surveillance Immunoprevention In Vitro Individual Infection Inherited Intercept Lesion Lung Lung Adenocarcinoma Malignant Neoplasms Medical Neisseria meningitidis Nodule Patients Poliomyelitis Predisposition Premalignant Neoplasm Prevention Prevention strategy Primary Cancer Prevention RNA RNA vaccination RNA vaccine Recording of previous events Recurrence Research Resource Sharing Role Science Services Smoker Sum Syndrome T-Lymphocyte Technology Translating Tumor Antigens Vaccines Validation Work biobank cancer genetics cancer genome cancer genomics cancer immunotherapy cancer predisposition cancer prevention cancer risk clinical translation cytotoxicity test efficacy testing experience flexibility immune RNA immunogenic immunogenicity in vivo in vivo Model individualized prevention innovation lipid nanoparticle mouse model neoantigens patient population pre-clinical programs success transcriptome tumor tumor immunology vaccine discovery vaccine formulation

项目摘要

Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically translated contributions to the field. Project 1 will develop and validate an LNP RNA immunoprevention vaccine for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens shared among cancers from different patients. Project 2 will develop and validate an LNP RNA immune interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including LNP RNA vaccine formulation, computational genomic tumor immunology, spatial genomics and immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically outstanding CRI External Advisory Board (EAB), which includes 2021 Lasker Award winner Drew Weissman (Penn) for his work on LNP RNA COVID19 vaccines. Overall, the CAP-IT CRI will develop state-of-the-art LNP RNA immunoprevention and immune interception vaccines and provide a technologically powerful platform to jumpstart additional CAP-IT CRI LNP RNA vaccine projects. We anticipate that CAP-IT CRI will propel both Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials within the next 5 years and FDA approval/clinical translation within ten years.

总体组成部分：项目摘要/摘要 CAP-IT RNA 免疫预防中心 (CRI) 的总体目标是在临床前描述、制定和验证脂纳米粒子 RNA (LNP RNA) 疫苗能否精确预防癌症增加的个体风险。 PI 是 Lipkin 博士，他是癌症预防领域的知名领导者，在临床上取得了多项重要成果。翻译对该领域的贡献。项目1将开发并验证LNP RNA免疫预防疫苗林奇综合征，一种具有高免疫原性复发性新抗原的遗传性癌症易感综合征不同患者的癌症共有。项目 2 将开发并验证 LNP RNA 免疫针对肺部非实性结节 (NSN) 癌前肿瘤患者的拦截疫苗腺癌前驱病变。为了实现这些目标，我们将使用最先进的技术，包括 LNP RNA 疫苗配方、计算基因组肿瘤免疫学、空间基因组学和免疫肽组学。为了确保 CRI 的科学严谨性和卓越性，我们组建了科学的杰出的 CRI 外部顾问委员会 (EAB)，其中包括 2021 年拉斯克奖获得者 Drew Weissman （宾夕法尼亚大学）表彰他在 LNP RNA COVID19 疫苗方面的工作。总体而言，CAP-IT CRI 将开发最先进的 LNP RNA 免疫预防和免疫拦截疫苗，并提供一个技术强大的平台启动其他 CAP-IT CRI LNP RNA 疫苗项目。我们预计 CAP-IT CRI 将推动两者林奇综合征和肺 NSN 疫苗将在未来 5 年内进行 NCI PREVENT 和 CP-NET 临床试验十年内 FDA 批准/临床转化。